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Summary
Tumor stage, age of patient, and amplification of MYCN predict disease outcome in neuroblastoma. To gain insight into
the underlying molecular pathways, we have obtained expression profiles from 94 primary neuroblastoma specimens.
Advanced tumor stages show a characteristic expression profile that includes downregulation of multiple genes involved
in signal transduction through Fyn and the actin cytoskeleton. High expression of Fyn and high Fyn kinase activity are
restricted to low-stage tumors. In culture, expression of active Fyn kinase induces differentiation and growth arrest of
neuroblastoma cells. Expression of Fyn predicts long-term survival independently of MYCN amplification. Amplification of
MYCN correlates with deregulation of a distinct set of genes, many of which are target genes of Myc. Our data demonstrate
a causal role for Fyn kinase in the genesis of neuroblastoma.
Introduction predicts poor survival, strongly suggesting that telomere attri-
tion limits tumor growth in vivo. A second factor is the differential
expression of members of the trk family of neurotrophin recep-Human neuroblastoma is a childhood tumor of the peripheral
sympathetic nervous system with a cumulative incidence of tors: whereas expression of TRKA correlates with good progno-
sis, expression of TRKB indicates poor long-term survival (Naka-16.9 cases per 100,000 children. The course of the disease
varies strongly in individual patients, ranging from spontaneous gawara et al., 1992, 1993). Signaling through TrkA negatively
regulates tumorigenicity of human neuroblastoma cells in a xe-regression to progressive disease and metastasis.
One genetic factor that predicts poor prognosis is the ampli- nograft model, arguing that the differential expression through
trk receptors is causally involved in neuroblastoma developmentfication of MYCN; enhanced expression of MYCN, as a conse-
quence of amplification, contributes to the progression of neuro- (Eggert et al., 2002).
Current clinical protocols use tumor stage and age of patientblastoma (Schwab et al., 1983; Brodeur et al., 1984). The protein
encoded by MYCN (N-Myc) is a transcription factor, which can in addition to amplified MYCN for prognosis and for decision
on therapeutic regimens (Berthold et al., 1997). Like increasedboth positively and negatively control gene expression (Eisen-
man, 2001). Models largely derived from tissue culture experi- age, advanced tumor stage is a strong predictor of poor survival.
But whether different tumor stages show consistent geneticments view Myc proteins as regulators of both cell growth and
proliferation (e.g., Elend and Eilers, 1999); whether such models differences, and whether such differences reflect alterations in
signaling pathways that control neuroblastoma proliferation andapply to human tumors remains unclear.
Little is known about molecular factors that influence the differentiation, is not clear.
We have now used cDNA microarray analysis of multipledevelopment of tumors lacking amplified MYCN. One such fac-
tor is the expression of HTERT, encoding the catalytic subunit of primary tumor biopsies to deduce expression profiles that char-
acterize both MYCN amplified tumors and nonamplified tumorstelomerase (Hiyama et al., 1995). Elevated expression of HTERT
S I G N I F I C A N C E
Human neuroblastoma is a childhood tumor with a wide range of clinical outcomes, ranging from spontaneous regression to tumor
progression and metastasis. We have used microarray analysis of primary tumor biopsies to obtain expression profiles and dissect
signaling pathways that control neuroblastoma development. Our data identify signal transduction through Fyn kinase as a novel
pathway that controls neuroblastoma cell differentiation and proliferation. Potentially, the results point to novel therapeutic strategies
that can be used in treating the disease.
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Table 1. Comparison of the clinical parameters of the 94 patients to the parameters of the 1378 tumors in the collection
Tumor included in the analysis (n  94)
1 2 3 4 4S All
MYCN nonamplified 19 8 17 21 12 77
MYCN amplified 1 1 4 8 3 17
% MYCN amplified 5 11.1 19 27.6 20 18.1
Age  12 months 18 1 11 5 15 50
Age  12 months 2 8 10 24 0 44
Mean (months) 4.3 23.4 28.7 42.6 4 23.3
% of all tumors 21.3 9.6 22.3 30.9 16 100
Tumor collection (n  1378)
1 2 3 4 4S All
MYCN nonamplified 307 171 233 331 141 1183
MYCN amplified 10 7 49 122 16 204
% MYCN amplified 3.2 3.9 17.4 26.9 10.2 14.7
Age  12 months 162 70 82 66 157 537
Age  12 months 155 108 200 387 0 850
Mean (months) 10.8 14.2 17.9 34.3 2.6 34.5
% of all tumors 22.9 12.8 20.3 32.7 11.3 100
of different stages. We find that both MYCN amplified tumors vates Src and Fyn kinase (Baisden et al., 2001); -catenin
(CTNNA1), whose binding to - and -catenin is regulatedand advanced tumor stages are characterized by distinct ex-
pression profiles. Specifically, our data identify signaling through through Fyn-dependent phosphorylation (Calautti et al., 1998);
neural cell adhesion protein (NRCAM), which signals throughthe Fyn nonreceptor kinase as a pathway that is downregulated
in advanced tumor stages in vivo and controls cellular differenti- nonreceptor tyrosine kinases (Ignelzi et al., 1994); and the actin
binding proteins tropomodulin (Gregorio et al., 1995) and myris-ation in vitro.
toylated alanine-rich C kinase substrate (MARCKS) (Brouns et
al., 2000; Yarmola et al., 2001).Results
In order to validate these data, we randomly picked 16 stage
1 and stage 4 out of the 94 tumors and measured the expressionIn order to gain insights into the molecular pathways governing
neuroblastoma development, we obtained expression profiles of FYN and AFAP by quantitative PCR; the results confirmed
the differences in mRNA expression detected in the microarrayfrom 94 individual tumor biopsies using a 4608 cDNA human
unigene chip. Each chip was hybridized to cDNA derived from a analysis (Supplemental Figure S1A at http://www.cancercell.
org/cgi/content/full/2/5/377/DC1). To extend these results, wehuman neuroblastoma cell line (SHEP) as reference. The tumors
were selected to reflect distribution of tumor stages and MYCN used Western blotting to measure levels of Fyn protein in a
group of 70 tumors; only five of these tumors were included inamplification in the total tumor bank of 1378 tumors (Table 1).
To permit interspot and interarray comparisons, each signal was the array analysis. The levels of Fyn protein varied widely be-
tween different tumors (Figure 3A). As expected from the mi-background corrected, and log2 transformed red/green intensity
ratios were calculated and standardized. Two-sample t statistics croarray analysis, expression of Fyn strictly correlated with tu-
mor stage, being detectable in most stage 1 tumors and absentand adjusted p values were used to identify differentially ex-
pressed genes (Callow et al., 2000). The adjusted p values cor- from most stage 4 tumors (Figure 3B). Consistent with the mi-
croarray data, low expression of Fyn was also observed inrect for testing 4608 genes at the same time and estimate the
overall probability of detecting one false gene (see Experimental MYCN amplified tumors (most of which are from stages 3 and
4), arguing that downregulation of Fyn in advanced tumor stagesProcedures).
Initial analysis revealed that, of the non-MYCN amplified occurs independently of MYCN amplification (see below). In
parallel, we picked 22 stage 1 and stage 4 tumors out of thetumors, stages 1 and 4, but not stages 2, 3, and 4S, showed
distinct expression profiles when compared with the remainder group of 70 tumors and determined Fyn kinase activity in ex-
tracts using immune-complex kinase assays, measuring bothof the tumors (data not shown). We found 24 significant genes
differentially expressed between stage 1 (n  19) and stage 4 autophosphorylation of Fyn and phosphorylation of the exoge-
nous substrate, enolase (Figures 3C and 3D). In agreement with(n  21) tumors (adjusted p value  0.05). 12 additional genes
had an adjusted p value between p  0.05 and 0.2 (Figure 1). the results obtained in Western blots, high Fyn kinase activity
was consistently observed in biopsies from stage 1 tumors. InUnsupervised cluster analysis shows that all but three tumors
were correctly assigned to the respective stage. Surprisingly, contrast, Fyn kinase activity was on average much lower in
extracts from stage 4 tumors. The p values for this distributiona significant percentage of genes that were differentially ex-
pressed encoded genes involved in signaling through the nonre- are below p  0.001, both for phosphorylation of enolase and
for autophosphorylation of Fyn. Fyn kinase activity closely paral-ceptor tyrosine kinase Fyn and the actin cytoskeleton. These
genes were coordinately downregulated in advanced stage neu- leled expression levels when both kinase activity and protein
levels were measured from the same tumor (compare Figuresroblastoma, both in MYCN amplified and nonamplified tumors
(Figures 2A and 2B). The group includes FYN itself; actin-fila- 3A and 3C), suggesting that regulation of FYN expression is
the major factor determining Fyn activity in these extracts. Wement binding protein (AFAP), a protein that binds to and acti-
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Figure 1. Identification of a tumor-stage-specific pattern of gene expression
Hierarchical cluster analysis of 21 stage 4 versus 19 stage 1 MYCN nonamplified tumors using 36 genes (adjusted p value  0.2) differentially expressed
between stage 4 and stage 1 tumors. Both genes and individual tumors are clustered in this diagram. Green designates downregulation of a gene in a
given tumor; red designates upregulation relative to the mean. The standard deviation () from the mean is indicated. Gray spots indicate missing data.
The table at the right provides the fold regulation, adjusted p value, and a functional annotation for each gene. The numbers at the top identify the
individual tumors. C, genes involved in cell cycle and checkpoints; M, genes involved in metabolism; P, protein synthesis; S, signal transduction.
concluded that expression of Fyn closely parallels tumor stage teristics of differentiation. In contrast, expression of a kinase-
negative allele (FynK299M) did not induce morphological differ-in human neuroblastoma.
Importantly, the biopsies subjected to Western blotting were entiation (Figure 5A; a quantitation of the results is shown in
Figure 5B). Coexpression of Fyn together with a membrane-derived from patients having a median observation time of 94.1
months, allowing us to evaluate the prognostic value of Fyn localized form of green fluorescent protein (EGFPF, carrying the
ras farnesylation signal; Jiang and Hunter, 1998) confirmed thatexpression. In a Kaplan-Meier analysis, expression of Fyn pre-
dicted survival with a p value of p 2	 10
4 for the total group the apparent differences in cell morphology were not due to
differential localization of Fynwt and FynK299M (Figure 5A).of 70 tumors and of p  0.00694 for the subset of nonamplified
tumors (n  58) (Figure 4A). Multivariate analysis with two pa- In order to demonstrate that the observed changes indeed
reflect a neuronal differentiation process, we stained transfectedrameters showed that expression of FYN predicted survival in-
dependently of MYCN amplification and was a better indicator cells with an antibody directed against GAP43, a protein that
is abundant in developing neurons and that has been causallyof prognosis than patient age (Figure 4B). As expected from
the analysis, expression of Fyn was strongly correlated to tumor implicated in the differentiation of neuroblastoma cells (e.g.,
Morton and Buss, 1992). Expression of Fynwt strongly upregu-stage and did not predict survival independently of stage.
To test whether FYN has a causal role in differentiation and lated expression of GAP43; in contrast, all cells expressing
FynK299M remained negative for GAP43 expression (Figure 5E).regulation of cell proliferation of neuroblastoma cells, we used
transient transfection to express Fyn in SH-SY5Y cells, a human Labeling of cells with BrdU or staining with antibodies directed
against cyclin A as a marker of cell proliferation revealed thatneuroblastoma cell line derived from a stage 4 tumor (Pahlman
et al., 1981). Expression of wild-type Fyn (Fynwt) induced the cells expressing active Fyn had exited from the cell cycle (Figure
5C). FACSscan analysis showed that cells expressing Fyn accu-extension of multiple neurites and overt morphological charac-
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Figure 2. Stage-specific expression of FYN,
CTNNA1, NRCAM, and AFAP
A: Expression profiles of the indicated genes in
stage 1 and stage 4 non-MYCN-amplified tu-
mors. All plots show log2 expression values relative
to stage 1.
B: Box plots documenting the distribution of FYN
and -catenin (CTNNA1) expression in nonampli-
fied tumors of different stages and in tumors car-
rying amplified MYCN. The symbols used in the
box plots are explained in the Experimental Pro-
cedures.
Figure 3. Regulation of Fyn kinase expression and
activity in neuroblastoma stages
A: The upper panel shows a Western blot analysis
of 16 (out of 70 tested) tumors documenting dif-
ferential expression of Fyn protein in stage 1 ver-
sus stage 4 tumors. Expression of Cdk2 was used
as a control (lower panel). The numbers identify
the individual tumors. The tumors were selected
to document expression differences of Fyn pro-
tein between tumors scored as negative and
positive (all stage 1 tumors and tumor 131).
B: Expression of Fyn protein is correlated with tu-
mor stage. The panel shows the number of
tumors scored as negative or positive for Fyn ex-
pression in a group of 70 tumors in relation to
tumor stage.
C: Immune-complex kinase assays document-
ing Fyn kinase activity measured either as Fyn
autophosphorylation or as phosphorylation of
enolase (see arrows) in 22 stage 1 and stage 4
tumors.
D: Quantitation of the results shown in C. Shown
is the kinase activity in each tumor relative to the
average activity in stage 4 tumors.
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Figure 4. Expression of Fyn is prognostic for long-
term survival of neuroblastoma patients
A: Kaplan-Meier diagrams documenting in-
creased survival probability of patients with tu-
mors that contain detectable amounts of Fyn
(Fyn) versus patients with tumors lacking detect-
able Fyn (Fyn
). The upper diagram shows sur-
vival probability in the total group of 70 tumors
that were analyzed; the lower diagram shows
survival probability in the 58 tumors that lack am-
plified MYCN.
B: Multivariate analysis using the parameters
age, stage, Fyn expression, and amplification of
MYCN. Statistically significant parameters are
shown in bold.
mulated in the G1 phase of the cell cycle (Figure 5D). We con- stage 4 tumors. In order to validate these observations, we
measured the expression of AUROR2, MYCN, and HSP75 included that Fyn induces G1 arrest and neuronal differentiation
of neuroblastoma cells. Consistent with a role of AFAP in activa- 16 randomly picked amplified and nonamplified tumors using
quantitative PCR (see Supplemental Figure S1B); the resultstion of Fyn, expression of a constitutively active allele of AFAP
induced morphological changes highly reminiscent of active confirmed the expression differences observed in the microarray
analysis.Fyn, while a dominant negative allele of AFAP did not affect
differentiation (not shown). Functional annotation showed that most genes that were
upregulated in MYCN amplified tumors encoded proteins thatWe repeated the experiments in IMR-32 cells, a human
neuroblastoma cell line that carries amplified MYCN (Clementi function in protein synthesis, metabolism, and cell cycle regula-
tion (see Supplemental Figure S2); this is consistent with mi-et al., 1986). Similar to results obtained in SH-SY5Y cells, ex-
pression of active Fyn kinase induced neurite extension and croarray data using inducible systems in tissue culture (Coller
et al., 2000; Guo et al., 2000; Menssen and Hermeking, 2002;cell cycle exit (Figure 5F). We concluded that the induction of
differentiation by Fyn occurs even in the presence of amplified O’Hagan et al., 2000; Schuhmacher et al., 2001). The findings
strongly support the notion that Myc proteins regulate both cellMYCN.
Expression of FYN did not discriminate between tumors that growth and cell proliferation and argue that models developed
in tissue culture extend to the genesis of neuroblastoma (Beierdo or do not have amplified MYCN (p  0.558 in the whole
group of 94 tumors; p  1.0 when adjusted for stage; see also et al., 2000; Eilers et al., 1991; Johnston et al., 1999; Schuh-
macher et al., 1999). A large group of genes that were mostlyFigure 2B). Also, the multivariate analysis showed that amplifi-
cation of MYCN and expression of FYN are independently prog- downregulated in MYCN amplified tumors encoded proteins
involved in multiple signal transduction pathways, supportingnostic for survival (Figure 4). Together, both findings strongly
suggest that amplification of MYCN does not promote tumor the notion that Myc proteins provide a negative feedback signal
to signaling pathways (Supplemental Figure S2) (Oster et al.,progression through regulation of FYN expression. We therefore
wondered whether there are genes that are specifically deregu- 2000). Surprisingly, the cell cycle genes that were upregulated
in MYCN amplified tumors encode proteins known to functionlated in MYCN amplified tumors. We found 123 differentially
expressed genes when comparing MYCN amplified (n  17) in checkpoint responses or in the G2 and M phases of the cycle,
pointing to novel functions of Myc in checkpoint control andand nonamplified (n  77) tumors (adjusted p value  0.05).
Using these genes in an unsupervised, hierarchical cluster anal- late in the cell cycle (Figure 6A) (see also Menssen and Herme-
king, 2002).ysis showed that all but two tumors were correctly assigned to
one of the two classes (see Supplemental Figure S2 at http:// To formally show that deregulation of these genes does
not simply reflect the advanced tumor stage of most MYCNwww.cancercell.org/cgi/content/full/2/5/377/DC1). With two
exceptions (SWIP1 and MAD2), this set of genes showed no amplified tumors, we compared their expression between stage
4 MYCN amplified and nonamplified tumors (Figure 6B). Theoverlap with the group of genes that discriminates stage 1 from
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Figure 5. Regulation of neuroblastoma cell differentiation and proliferation by Fyn
A: Immunofluorescence pictures of SH-SY5Y cells showing the morphology of representative cells transfected with expression plasmids encoding Fynwt
(upper three panels) or FynK299M (lower three panels) together with a plasmid encoding a GFP that is targeted to the plasma membran (EGFPF). Left
panels show staining with an antibody directed against Fyn, middle panels show GFP fluorescence, and right panels show the overlay together with Hoechst
staining to visualize nuclei.
B: Quantitation of the results obtained. Shown is the percentage of cells with the indicated numbers of neurites after transfection with the indicated
expression plasmids (100 Fyn-positive cells were counted for each experiment).
C: Percentage of cells incorporating BrdU (upper panel) or staining positive for cyclin A (lower panel) of SH-SY5Y cells transfected with an expression vector
encoding Fynwt. Cells were stained both for Fyn and for cyclin A or BrdU and Fyn-positive and -negative cells were counted separately.
D: FACSscan analysis documenting accumulation in the G1 phase of the cell cycle of SH-SY5Y cells expressing Fyn. Cells were transfected with a plasmid
encoding a Fyn-GFP chimerical protein and subjected to cell cycle analysis (using propidium iodide staining) after gating for GFP-positive and -negative
cells.
E: Immunofluorescence pictures of SH-SY5Y cells showing expression of GAP43 in cells expressing Fynwt (upper panels) but not in cells expressing FynK299M
(lower panels). The right panels show cells stained with an antibody directed against Fyn, the middle panels show staining with an -GAP43 antibody, and
the right panels show the overlay together with Hoechst staining to visualize nuclei.
F: The left panels show immunofluorescence pictures documenting the morphology of IMR-32 cells upon expression of Fynwt or FynK299M. The right panel
documents the percentage of IMR-32 cells expressing cyclin A.
expression of all genes that we analyzed was regulated by targets of N-Myc, we searched for potential binding sites for
N-Myc (E boxes) in the promoter region and introns of the sixMYCN amplification independent of tumor stage. Conversely,
deregulation of expression might be a consequence of MYCN regulated genes. Potential N-Myc binding sites were found in
four of them (Figure 6E and data not shown). We then performedamplification. Indeed, expression of a panel of genes identified
as target genes of (c-)Myc in tissue culture experiments was sig- chromatin-immunoprecipitation experiments, using the prothy-
mosin- gene (PTMA, see Figure 6B) as positive control. In vivonificantly different between both classes of tumors (Figure 6C).
To extend these observations, we asked whether additional binding of N-Myc was detected to E boxes in the MAD2, HSP75,
and FACL2 genes, strongly suggesting that they are directlygenes contained on the list are target genes that are regulated
by N-Myc. In order to address this question, we analyzed the regulated by N-Myc in vivo (Figure 6E). No binding was detected
to the E boxes in the AURORA2 gene. Taken together, our dataexpression of eight randomly chosen genes in a cell line that
carries a tetracycline regulatable allele of N-Myc (Lutz et al., suggest that a significant fraction of the genes that discriminate
MYCN amplified from nonamplified tumors are regulated as a1996). Of those, six genes were induced in response to induction
of MYCN expression (Figure 6D); no regulation was observed consequence of MYCN amplification, since they are direct or
indirect targets for transcriptional regulation by N-Myc.for two genes (EFNB3 and SWIP1), suggesting that their deregu-
lation in MYCN amplified tumors may reflect events in tumori-
genesis that cannot be mimicked in tissue culture. In addition, Discussion
we did not observe any regulation of FYN expression by MYCN
in this cell line (Figure 6D). Previous work has identified amplification of MYCN as a genetic
event that strongly affects neuroblastoma development. WhileTo determine whether some of these genes are indeed direct
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Figure 6. Characterization of genes that are dif-
ferentially expressed in MYCN amplified tumors
A: Boxplots documenting enhanced expression
of multiple genes involved in G2 progression and
checkpoint functions in MYCN amplified tumors
(white boxes) versus nonamplified tumors (gray
boxes).
B: Boxplots documenting expression of 10 differ-
entially expressed genes in stage 4 tumors, either
with (white boxes) or without (gray boxes) ampli-
fied MYCN. The 10 genes from Supplemental Fig-
ure S2 with the lowest p values are shown.
C: Multiple known target genes of Myc are differ-
entially regulated in MYCN amplified versus
nonamplified tumors. White boxes indicate ex-
pression in amplified tumors, gray boxes in non-
amplified tumors. All known target genes up to
an adjusted p value of p  0.05 are listed. All
genes shown are upregulated by Myc in culture
with the exception of PDGFB, which is repressed
by Myc.
D: Multiple genes that are differentially expressed
in MYCN amplified tumors are regulated by
N-Myc in culture. Shown are the results of quanti-
tative PCR experiments documenting expression
of the indicated genes in a neuroblastoma cell
line carrying a tetracycline-regulatable allele of
MYCN (Lutz et al., 1996). The plot shows the cycle-
threshold value for each gene relative to -actin.
E: Chromatin immunoprecipitation assays docu-
menting direct binding of N-Myc to E boxes local-
ized in the indicated genes. The left panel shows
binding of N-Myc to the E box in the first intron
of the PTMA gene as positive control (Gaubatz
et al., 1994). The right panel shows absence of
binding to exon sequences of the MAD2 genes
as negative control. “Con.ab” designates a con-
trol antibody, “
ab” designates a control with-
out primary antibody. The position of the E box
in each gene is indicated in brackets.
tumors that carry amplified MYCN have an extremely poor prog- significantly different between MYCN amplified and nonampli-
fied tumors. In addition, induction of MYCN does not regulatenosis, less was known about the factors that control neuro-
blastoma development in tumors that lack amplified MYCN. expression of FYN in culture. In culture, active Fyn kinase in-
duces cell cycle arrest and morphological differentiation in bothWe now identify signal transduction through the nonreceptor
tyrosine kinase Fyn as one pathway that controls neuroblastoma neuroblastoma cell lines that do or do not have amplified MYCN.
Conversely, microarray analysis defines a distinct group ofdevelopment in both MYCN amplified and nonamplified tumors.
This conclusion is based on four lines of evidence. First, array genes that are differentially regulated in MYCN amplified tumors.
This set of genes shows almost no overlap with the stage-analysis identifies multiple genes that encode proteins, which
are functionally linked to FYN, as a group of genes coordinately specific group of genes that point to the role of FYN in neuro-
blastoma. Further analysis suggests that a significant proportiondownregulated in advanced stage tumors. Second, Western
blotting and kinase assays show that Fyn expression and kinase of the genes that are deregulated in MYCN amplified tumors
are either direct or indirect downstream targets of N-Myc; mostactivity is strongly correlated with tumor stage. Third, expression
levels of Fyn predicts prognosis in neuroblastoma. Fourth, active likely, therefore, they are regulated in response to MYCN ampli-
fication. Taken together, our data strongly suggest that signalFyn kinase induces cell cycle arrest and differentiation in cul-
tured neuroblastoma cells. transduction through Fyn and amplification of MYCN define
distinct molecular pathways that independently control neuro-Several observations suggest that FYN regulates neuro-
blastoma development independently of MYCN amplification. blastoma development.
FYN is neither mutated nor does it show LOH in neuro-For example, expression of Fyn predicts prognosis in tumors
that do not carry amplified MYCN as well as in the total group blastoma. Therefore, the genetic factors that lead to downregu-
lation of FYN expression in advanced stage neuroblastoma re-of tumors; multivariate analysis indeed shows that expression of
Fyn and MYCN status are independently prognostic for survival. main unclear.
Fyn kinase has been causally implicated in the differentiationConsistent with these observations, expression of FYN is not
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channels were obtained. To account for spot differences, the backgroundof both oligondendrocytes and keratinocytes (Cabodi et al.,
corrected ratio of the two channels was calculated and log2-transformed.2000; Calautti et al., 1995; Wolf et al., 2001). Downregulation
To balance the fluorescence intensities for the two dyes, as well as toof FYN in advanced tumor stages may therefore contribute to
allow for comparison of expression levels across experiments, the raw data
the loss of differentiated features and enhanced cell proliferation was standardized. First, we used a pin-wise intensity-dependent standard-
in advanced tumor stages. In tissue culture and in transgenic ization (Yang et al., 2002) to correct for inherent bias on each chip (the
mice, signaling through Fyn has also been implicated in neurite lowess scatter-plot smoother). In a second step, a global standardization
was applied to center the log-ratios for each array at zero (to account forextension and cell adhesion (Brouns et al., 2000, 2001). Ad-
global staining and scanner effects). As each gene was spotted twice onvanced tumor stages are also characterized by their ability to
the chip, mean log-ratios M were calculated from replicates. If gene replicatesinvade lymph nodes and form metastases. It is also possible,
differed more than 4-fold or the background intensity was higher than signal
therefore, that downregulation of FYN and altered cell adhe-
intensity, the gene was excluded on that array.
sion contribute to these invasive properties of neuroblastoma In total, less than 2% of the genes had to be flagged and filtered out.
tumors. The correlation coefficient between spot replicas on one chip is between
0.8 and 1.0 for 79% of the chips, and between 0.7 and 0.8 for the remaining.Several possibilities exist as to how active FYN may exert
its function. In neuronal cells, nonreceptor tyrosine kinases
Statistical analysisphosphorylate Rho-GAP, leading to inactivation of Rho and
The final data matrix consisted of 4608 standardized gene expressionsinduction of differentiation (Brouns et al., 2001). In mouse mela-
measurements (log2-ratios) from 94 individual tumors (with missing values).nocytes, active Fyn kinase induces a lasting activation of the To compare the expression profile between two independent groups, the
MAPkinase pathway through inhibition of MAPkinase phospha- two-sample t statistic was used for every gene. To account for multiple
tase 1 (Wellbrock et al., 2002); persistent MAPkinase activation testing, we computed adjusted p values for each gene using a step-down
permutation algorithm (Westfall and Young, 1993; algorithm 4.1). This strat-has similarly been shown to induce neuronal differentiation (Qui
egy has been previously applied to microarrays (Callow et al., 2000). Theand Green, 1992). We suggest that downstream signaling mole-
permutation algorithm provides strong control of the familywise error ratecules that are inhibited by Fyn may be targets for therapeutic
(FWER) and takes into account correlation of the variables (genes). Theintervention in neuroblastoma. For example, Rho exerts its bio-
procedure does not rely upon a normality assumption. Evaluating all genes
logical functions in part through activation of Rho-kinase (e.g., with an adjusted p value of less than 5%, for example, means that the
Sahai and Marshall, 2002). If inhibition of Rho and of Rho-kinase probability of having one or more false positive genes within the whole list
is less than 5%. The log-rank test was used for statistical comparison ofis critical for the effects of FYN in neuroblastoma, inhibition of
survival curves, and Cox’s model for multivariate analysis.Rho-kinase might mimic the cell cycle arrest and differentiation-
inducing effects of Fyn. Similarly, Fyn kinase activity is nega-
Cluster analysistively regulated through phosphorylation of Fyn by Csk in vivo,
Prior to the cluster analysis, the expression profile of each gene was stan-
and inhibition of Csk might therefore lead to activation of endog- dardized to mean 0 and variance 1. Average linkage hierarchical clustering
enous Fyn kinase even when expression levels are low (Imamoto was then performed for genes as well as for chips using the Euclidean
and Soriano, 1993). In this respect, we suggest that interference distance metric as implemented in the program J-Express (Dysvik and
Jonassen, 2001).with signaling through Fyn may provide a therapeutic avenue
for advanced stage neuroblastoma.
Representation of expression data
Expression data of individual genes are shown as box plots. For a detailedExperimental procedures
description of these plots, see http://www.ruf.rice.edu/lane/hyperstat/
A37797.html. Briefly, the line in the middle represents the median of theMicroarray experiments
expression. The whiskers show the upper and lower range of data, up toThe chip we used contains the gf200 set of Research Genetics cDNAs
1.5	 the box length from the median. The box shows the range of data(http://www.resgen.com) and an additional 90 cDNAs that had previously
between the 25th and 75th percentiles. An outlier (more than 1.5	 the boxbeen described as potentially prognostic for neuroblastoma development
length from the median) is shown as a circle.(for details, see http://www.imt.uni-marburg.de). Each cDNA was spotted
twice per chip. Chips were generated as described in Hegde et al. (2000)
Real-time RT-PCT analysisusing a GMS 417 arrayer. All genes that were selected for further analysis
10 g of total RNA were reverse transcribed using Superscript II Reversewere resequenced to confirm their identity.
transcriptase and an oligodT15 primer according to the manufacturer’s in-Initial histochemistry of a series of 100 randomly picked tumors revealed
structions. Real time PCR was performed on a Biorad I-Cycler using Sybrthat approximately 95% of the tumors had less than 5% nontumor cells in
Green as detection agent; the products were detected using a 490 nm filter.the biopsies we used (Bergmann et al., 2001 and data not shown). Therefore,
Primer pairs specific for AURORA2, FACL2, FYN, GMPS, KARS, MAD2, andno further attempt was made to dissect tumor tissue before preparation of
MYCN are available upon request.RNA. Total RNA from neuroblastoma tissue and SHEP was isolated using
a Qiagen RNA isolation kit according to manufacturers’ instructions. 40 g
Western blots and immunoprecipitationtotal RNA was used to synthesize Cy3- and Cy5-fluorescently labeled cDNA
The following antibodies were used in Western blots, immunofluorescenceaccording to published protocols (http://brownlab.stanford.edu). Chips were
experiments, and immunoprecipitations: -Fyn (sc-434), -cdk2 (sc-163),scanned using a GMS 418 fluorescent scanner and the images analyzed
and -cyclinA (sc-751) (all Santa Cruz); -BrdU (Amersham); and -GAP43using IMAGENE 3.0 software. Expression data were validated using either
(Novus Biochemicals NB300-1434A1). Neuroblastoma tissue was lysed asNorthern blot analysis (data not shown) or real-time RT-PCR assays (see
described elsewhere (Bergmann et al., 2001).Supplemental Figure S1 at http://www.cancercell.org/cgi/content/full/2/5/
377/DC1).
In vitro kinase assays
500 g cellular proteins were immunoprecipitated with 5 g -Fyn antibodyStandardization and quality control
bound to protein G beads, washed and equilibrated in kinase assay buffer,ImaGene 3.0. software parameters like “signal range” or “spot detection
incubated 15 min with 10 Ci -ATP (Amersham) and 0.125 mg/ml enolase,threshold” (see ImaGene user’s manual for details) were optimized for maxi-
mum reproducibility prior to the image analysis of our experiment (data not electrophoresed on a 10% SDS PAGE, and dried. Results were visualized
on a Fuji phosphoimager and quantified using Image Gauge software.shown). For each spot, median signal and background intensities for both
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(1984). Amplification of N-myc in untreated human neuroblastomas corre-Chromatin immunoprecipitation
lates with advanced disease stage. Science 224, 1121–1124.Chromatin immunoprecipitation was performed as previously described
(Bouchard et al., 2001). Nuclear extracts from IMR-32 were immunoprecipi- Brouns, M.R., Matheson, S.F., Hu, K.Q., Delalle, I., Caviness, V.S., Silver,
tated overnight at 4C with 3 g -N-Myc antibody or control antibody J., Bronson, R.T., and Settleman, J. (2000). The adhesion signaling molecule
bound to protein A and G beads. For PCR analysis, specific primer pairs p190 RhoGAP is required for morphogenetic processes in neural develop-
for intron 1 of prothymosin  (as positive control) as well as primer pairs ment. Development 127, 4891–4903.
amplifying the indicated genomic regions were used. Primer sequences are
Brouns, M.R., Matheson, S.F., and Settleman, J. (2001). p190 RhoGAP isavailable upon request.
the principal Src substrate in brain and regulates axon outgrowth, guidance
and fasciculation. Nat. Cell Biol. 3, 361–367.Tissue culture experiments
SH-SY5Y and IMR-32 neuroblastoma cell lines were grown in RPMI 1640 Cabodi, S., Calautti, E., Talora, C., Kuroki, T., Stein, P.L., and Dotto, G.P.
supplemented with 10% heat-inactivated FCS. CMV-driven expression con- (2000). A PKC-eta/Fyn-dependent pathway leading to keratinocyte growth
structs encoding Fynwt and FynK299M were a kind gift from M. Resh and arrest and differentiation. Mol. Cell 6, 1121–1129.
have been described (Wolf et al., 2001). Plasmids encoding AFAPLZ and
Calautti, E., Missero, C., Stein, P.L., Ezzell, R.M., and Dotto, G.P. (1995).AFAP180-226 have been described in Baisden et al. (2001). For transient
fyn tyrosine kinase is involved in keratinocyte differentiation control. Genestransfections, cells were first grown on coverslips coated with a 1:5 dilution
Dev. 9, 2279–2291.
of Matrigel (Becton-Dickinson) for 6 hr. Transfection was performed using
5 g of DNA and Lipofectin Reagent (Invitrogen). Cells were fixed with Calautti, E., Cabodi, S., Stein, P.L., Hatzfeld, M., Kedersha, N., and Paolo
Dotto, G. (1998). Tyrosine phosphorylation and src family kinases controlparaformaldehyde after 48 hr, washed, and stained with monoclonal -Fyn
keratinocyte cell-cell adhesion. J. Cell Biol. 141, 1449–1465.antibody (Santa Cruz) or -AFAP rabbit-polyclonal antibody (Baisden et
al., 2001). BrdU labeling and immunofluorescence of transfected cells was
Callow, M.J., Dudoit, S., Gong, E.L., Speed, T.P., and Rubin, E.M. (2000).
performed as described previously (Rudolph et al., 1996). Microarray expression profiling identifies genes with altered expression in
For FACSscan analysis, SH-SY5Ycells were transfected with a plasmid HDL-deficient mice. Genome Res. 10, 2022–2029.
encoding a chimerical FYN-EGFP protein (kind gift of Marilyn Resh). 48 hr
Clementi, F., Cabrini, D., Gotti, C., and Sher, E. (1986). Pharmacologicalafter transfections, cells were fixed in ethanol and stained with propidium
characterization of cholinergic receptors in a human neuroblastoma cell line.iodide. Samples were gated for GFP-positive and -negative cells and then
J. Neurochem. 47, 291–297.analyzed separately.
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